View Item 

Show simple item record

Trends in imaging after diagnosis of thyroid cancer
dc.contributor.authorWiebel, Jaime L.en_US
dc.contributor.authorBanerjee, Mousumien_US
dc.contributor.authorMuenz, Daniel G.en_US
dc.contributor.authorWorden, Francis P.en_US
dc.contributor.authorHaymart, Megan R.en_US
dc.date.accessioned2015-05-04T20:36:52Z
dc.date.available2016-07-05T17:27:59Zen
dc.date.issued2015-05-01en_US
dc.identifier.citationWiebel, Jaime L.; Banerjee, Mousumi; Muenz, Daniel G.; Worden, Francis P.; Haymart, Megan R. (2015). "Trends in imaging after diagnosis of thyroid cancer." Cancer 121(9): 1387-1394.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/111216
dc.publisherSpringer‐Verlagen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherradioiodine scanen_US
dc.subject.othersurveillance imagingen_US
dc.subject.otherdifferentiated thyroid canceren_US
dc.subject.otherpositron emission tomography (PET) scanen_US
dc.subject.otherneck ultrasounden_US
dc.titleTrends in imaging after diagnosis of thyroid canceren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/111216/1/cncr29210.pdf
dc.identifier.doi10.1002/cncr.29210en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferencePalaniswamy SS, Subramanyam P. Diagnostic utility of PETCT in thyroid malignancies: an update. Ann Nucl Med. 2013; 27: 681 ‐ 693.en_US
dc.identifier.citedreferenceGreene FP, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer‐Verlag; 2002.en_US
dc.identifier.citedreferencePercy C, Fritz A. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.en_US
dc.identifier.citedreferenceNational Cancer Institute. SEER Stat Fact Sheets: Thyroid Cancer. seer.cancer.gov/statfacts/html/thyro.html. Accessed July 26, 2014.en_US
dc.identifier.citedreferenceHu YY, Kwok AC, Jiang W, et al. High‐cost imaging in elderly patients with stage IV cancer. J Natl Cancer Inst. 2012; 104: 1164 ‐ 1172.en_US
dc.identifier.citedreferenceWitkowski ER, Smith JK, Ragulin‐Coyne E, Ng SC, Shah SA, Tseng JF. Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study. J Gastrointest Surg. 2012; 16: 121 ‐ 128.en_US
dc.identifier.citedreferenceDinan MA, Curtis LH, Carpenter WR, et al. Variations in use of PET among Medicare beneficiaries with non‐small cell lung cancer, 1998‐2007. Radiology. 2013; 267: 807 ‐ 817.en_US
dc.identifier.citedreferenceRueth NM, Xing Y, Chiang YJ, et al. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage‐specific surveillance strategies. Ann Surg. 2014; 259: 1215 ‐ 1222.en_US
dc.identifier.citedreferencePrasad SM, Gu X, Lipsitz SR, Nguyen PL, Hu JC. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer. 2012; 118: 1260 ‐ 1267.en_US
dc.identifier.citedreferenceHaber RS. Role of ultrasonography in the diagnosis and management of thyroid cancer. Endocr Pract. 2000; 6: 396 ‐ 400.en_US
dc.identifier.citedreferenceMazzaferri EL, Kloos RT. Is diagnostic iodine‐131 scanning with recombinant human TSH useful in the follow‐up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab. 2002; 87: 1490 ‐ 1498.en_US
dc.identifier.citedreferenceVera P, Kuhn‐Lansoy C, Edet‐Sanson A, et al. Does recombinant human thyrotropin‐stimulated positron emission tomography with [18F]fluoro‐2‐deoxy‐D‐glucose improve detection of recurrence of well‐differentiated thyroid carcinoma in patients with low serum thyroglobulin? Thyroid. 2010; 20: 15 ‐ 23.en_US
dc.identifier.citedreferenceDennis K, Hay JH, Wilson DC. Effect of (18)F‐fluorodeoxyglucose positron emission tomography/computed tomography‐guided management of suspected recurrent papillary thyroid carcinoma: long‐term follow‐up with tumour marker responses. Clin Oncol (R Coll Radiol). 2012; 24: e168 ‐ e172.en_US
dc.identifier.citedreferenceCreach KM, Nussenbaum B, Siegel BA, Grigsby PW. Thyroid carcinoma uptake of 18F‐fluorodeoxyglucose in patients with elevated serum thyroglobulin and negative 131I scintigraphy. Am J Otolaryngol. 2013; 34: 51 ‐ 56.en_US
dc.identifier.citedreferenceWang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000; 85: 1107 ‐ 1113.en_US
dc.identifier.citedreferenceCenters for Medicare and Medicaid Services. National Coverage Determination (NCD) for PET Scans. cms.gov/medicare‐coverage‐database/details/ncd‐details.aspx?NCDId=211&ncdver=3&NCAId=104&NcaName=P ositron+Emission+Tomography+(FDG)+and+Other+Neuroimaging+Devices+for+Suspected+Dementia&IsPopup=y&bc=AAAAAAAAAEAAAA%3d%3d&. Accessed July 8, 2014.en_US
dc.identifier.citedreferenceIyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011; 117: 4439 ‐ 4446.en_US
dc.identifier.citedreferenceLin HW, Bhattacharyya N. Survival impact of treatment options for papillary microcarcinoma of the thyroid. Laryngoscope. 2009; 119: 1983 ‐ 1987.en_US
dc.identifier.citedreferenceGoffredo P, Roman SA, Sosa JA. Have 2006 ATA practice guidelines affected the treatment of differentiated thyroid cancer in the United States? Thyroid. 2014; 24: 463 ‐ 471.en_US
dc.identifier.citedreferenceButler Nattinger A, Schapira MM, Warren JL, Earle CC. Methodological issues in the use of administrative claims data to study surveillance after cancer treatment. Med Care. 2002; 40 ( suppl 8 ): IV ‐ 69‐IV‐74.en_US
dc.identifier.citedreferenceWarren JL, Harlan LC, Fahey A, et al. Utility of the SEER‐Medicare data to identify chemotherapy use. Med Care. 2002; 40 ( suppl 8 ): IV ‐ 55‐IV‐61.en_US
dc.identifier.citedreferenceKowalczyk KJ, Harbin AC, Choueiri TK, et al. Use of surveillance imaging following treatment of small renal masses. J Urol. 2013; 190: 1680 ‐ 1685.en_US
dc.identifier.citedreferenceWarren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER‐Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 ( suppl 8 ): IV ‐ 3‐IV‐18.en_US
dc.identifier.citedreferenceMorris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013; 23: 885 ‐ 891.en_US
dc.identifier.citedreferenceSmith‐Bindman R, Miglioretti DL, Johnson E, et al. Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996‐2010. JAMA. 2012; 307: 2400 ‐ 2409.en_US
dc.identifier.citedreferenceBhargavan M, Sunshine JH. Utilization of radiology services in the United States: levels and trends in modalities, regions, and populations. Radiology. 2005; 234: 824 ‐ 832.en_US
dc.identifier.citedreferenceGimbel RW, Fontelo P, Stephens MB, et al. Radiation exposure and cost influence physician medical image decision making: a randomized controlled trial. Med Care. 2013; 51: 628 ‐ 632.en_US
dc.identifier.citedreferenceHyder O, Dodson RM, Mayo SC, et al. Post‐treatment surveillance of patients with colorectal cancer with surgically treated liver metastases. Surgery. 2013; 154: 256 ‐ 265.en_US
dc.identifier.citedreferenceHyder O, Dodson RM, Weiss M, et al. Trends and patterns of utilization in post‐treatment surveillance imaging among patients treated for hepatocellular carcinoma. J Gastrointest Surg. 2013; 17: 1774 ‐ 1783.en_US
dc.identifier.citedreferenceVargas GM, Sheffield KM, Parmar AD, Han Y, Brown KM, Riall TS. Physician follow‐up and observation of guidelines in the post treatment surveillance of colorectal cancer. Surgery. 2013; 154: 244 ‐ 255.en_US
dc.identifier.citedreferenceHahn EE, Hays RD, Kahn KL, Litwin MS, Ganz PA. Use of imaging and biomarker tests for posttreatment care of early‐stage breast cancer survivors. Cancer. 2013; 119: 4316 ‐ 4324.en_US
dc.identifier.citedreferenceDavies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014; 140: 317 ‐ 322.en_US
dc.identifier.citedreferenceNational Cancer Institute. Cancer Trends Progress Report‐2011/2012 Update. progressreport.cancer.gov. Accessed July 15, 2014.en_US
dc.identifier.citedreferenceAmerican Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19: 1167 ‐ 1214.en_US
dc.identifier.citedreferenceCobin RH, Gharib H, Bergman DA, et al; Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract. 2001; 7: 202 ‐ 220.en_US
dc.identifier.citedreferencePacini F, Castagna MG, Brilli L, Pentheroudakis G, ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2012; 23 ( suppl 7 ): vii110 ‐ vii119.en_US
dc.identifier.citedreferenceRosario PW, Furtado Mde S, Mineiro Filho AF, Lacerda RX, Calsolari MR. Value of diagnostic radioiodine whole‐body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence. Thyroid. 2012; 22: 1165 ‐ 1169.en_US
dc.identifier.citedreferenceLal G, Fairchild T, Howe JR, Weigel RJ, Sugg SL, Menda Y. PET‐CT scans in recurrent or persistent differentiated thyroid cancer: is there added utility beyond conventional imaging? Surgery. 2010; 148: 1082 ‐ 1089; discussion 1089‐1090.en_US
dc.identifier.citedreferenceNational Cancer Institute. Overview of the SEER Program. seer.cancer.gov/about/overview.html. Accessed July 7, 2014.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr29210.pdf
Size:
339.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.